Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00368) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
Montelukast
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Approved/Marketed Drug
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5281040"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Cytochrome P450 2C8 (CYP2C8) | DME Info | Homo sapiens | [1] | |||
| Xenobiotics-DME Activity Data | ||||||
| Xenobiotics-DME Activity Data | Cytochrome P450 2C8 (CYP2C8) | DME Info | IC50 = 1 microM | [1] | ||
| References | ||||||
| 1 | Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J Med Chem. 2018 Jan 11;61(1):224-250. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.